CD4 News and Research

RSS

Scientists develop synthetic molecule effective at kicking and killing HIV

Current anti-AIDS drugs are highly effective at making HIV undetectable and allowing people with the virus to live longer, healthier lives. The treatments, a class of medications called antiretroviral therapy, also greatly reduce the chance of transmission from person to person.

5 Oct 2017

HIV cases on the rise among those in their 50s in Europe

A new study has found that one in every six persons diagnosed with HIV is over the age of 50 years. This new study was published yesterday (26th September 2017) in the journal Lancet HIV.

27 Sep 2017

Researchers overcome major stumbling blocks in developing HIV vaccine

An international team of researchers has demonstrated a way of overcoming one of the major stumbling blocks that has prevented the development of a vaccine against HIV: the ability to generate immune cells that stay in circulation long enough to respond to and stop virus infection.

13 Sep 2017

Chronic stress triggers fatal organ failure via new neural pathway

New research reveals the mechanisms behind the effects of chronic stress and tiny inflammations in the brain on fatal gut failure.

21 Aug 2017

Latency reversing agent makes dormant HIV-infected cells vulnerable to clearance

The ability for HIV to hide in the body in a dormant state makes curing the 40 million people living with the virus a challenge. Researchers at the University of North Carolina at Chapel Hill have shown the drug Vorinostat reverses this latency, causing resting CD4 T-cells to express HIV.

1 Aug 2017

HIV hides in more types of bone marrow cells than previously thought, research shows

Every day, 17 million HIV-infected people around the world swallow pills that keep the virus inside them at bay.

1 Aug 2017

Cocktail of drugs for HIV patients with advanced immunosuppression reduced deaths by 27%, study shows

A study published in the New England Journal of Medicine on 20th July 2017 suggests that a cocktail of drugs, if provided at the beginning of the HIV therapy, can save over 10,000 lives per year. HIV, which is often diagnosed late, leaves people vulnerable to other diseases by ravaging the immune system.

25 Jul 2017

At-risk alcohol use linked to lower ART adherence among people with HIV/AIDS

Advancements in antiretroviral therapy (ART) have allowed people living with HIV/AIDS to maintain a quality of life similar to those without HIV infection.

6 Jul 2017

Study: Personalized neoantigen vaccine stimulates strong anti-tumor response in melanoma patients

A personal cancer treatment vaccine that targets distinctive "neoantigens" on tumor cells has been shown to stimulate a potent, safe, and highly specific immune anti-tumor response in melanoma patients, report scientists from Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard.

5 Jul 2017

Finnish researchers find accumulation of gene mutations in some patients with rheumatoid arthritis

Gene mutations accumulating in cells are typical of the development of cancer. Finnish researchers found that a similar accumulation of mutations occurs also in some patients with rheumatoid arthritis.

21 Jun 2017

Supportive housing linked to improvements in health of formerly homeless people with HIV/AIDS

Ask Elizabeth Bowen about the intersection of homelessness and HIV/AIDS in the United States and she'll respond without hesitation, "Housing equals health."

1 Jun 2017

Scientists create a faster, less labor-intensive test to detect “hidden” HIV

The search to develop a HIV cure has long been overwhelmed by a seemingly simple question: How do physicians find out if somebody is cured? The virus has an ability to lie dormant in immune cells at levels that could not be detected to all, however, the most expensive and time-consuming tests can find the hidden virus.

30 May 2017

Dual therapy effective as second-line treatment for patients infected by HIV with multiple mutations

ANRS 12286 MOBIDIP, a clinical trial running in parallel in three countries in sub-Saharan Africa (Cameroon, Burkina Faso, and Senegal), shows that dual therapy with lamivudine and a boosted protease inhibitor is effective as second-line treatment in patients infected by HIV with multiple mutations.

29 May 2017

Study identifies two T cell biomarkers that may predict survival trajectory of IPF patients

Two T cell biomarkers appear to predict the survival trajectory of patients with idiopathic pulmonary fibrosis (IPF), a lung disease that has a varied, but ultimately devastating, impact on patients, according to new research presented at the ATS 2017 International Conference.

22 May 2017

Phase 1 clinical studies reveal safety, tolerability of therapeutic vaccine in celiac disease patients

ImmusanT, Inc., a clinical-stage company developing Nexvax2, a therapeutic vaccine intended to protect against the effects of gluten exposure while maintaining a gluten-free diet in HLA-DQ2.5+ patients with celiac disease, today announced the publication of positive data from two Phase 1 clinical trials of Nexvax2 in celiac disease.

12 May 2017

Introduction of ART has increased life expectancy in HIV patients by 10 years

A study published in the journal The Lancet HIV has found an increase in life expectancy of 20-year-old HIV patients in the EU and North America who had started antiretroviral therapy (ART) after it was introduced mid-1990s. When compared with patients who were not treated with ART, the life expectancy had increased by around a decade in these patients.

11 May 2017

Researchers find new way to prevent graft-versus-host disease after stem cell transplants

Through experimental work, an international team of researchers led by City of Hope's Defu Zeng, professor of diabetes immunology and hematopoietic cell transplantation, believe they may have found a way to prevent graft-versus-host disease after stem cell transplants while retaining the transplants' positive effects on fighting leukemia and lymphoma.

18 Apr 2017